Month: April 2020

First quarter of 2020A resilient profile and a strong balance sheetto face an unprecedented situationRevenue at € 2,834 million-0.8% organic growthBook to bill ratio at 103%Renewals of major contracts in North AmericaAppropriate business mix to support customers in Covid-19 contextNecessary cost actions being implemented to protect operating marginSPRING transformation program to an Industry approach well on trackUpdate of 2020 objectives post Covid-19Paris, April 22, 2020 – Atos, a global leader in digital transformation, today announces the revenue of its first quarter of 2020.Elie Girard, CEO, said: “In this unprecedented environment where uncertainty prevails, our first priority has been to protect our employees while offering full continuity of service to our clients. The Group is solidly positioned to navigate smoothly...

Premier trimestre 2020Un profil résilient et un bilan solide pour faire face à une situation sans précédentChiffre d’affaires à 2 834 millions d’euros-0,8% de croissance organiqueRatio prise de commandes sur chiffre d’affaires à 103%Renouvellement de contrats majeurs en Amérique du NordUn mix d’activités approprié pour soutenir les clients dans le contexte de Covid-19Les actions nécessaires sur les coûts ont été mises en place pour préserver la marge opérationnelleLa mise en place du programme de transformation SPRING pour une approche sectorielle est en bonne voieMise à jour des Objectifs 2020 post Covid-19Paris, le 22 avril 2020 – Atos, leader international de la transformation digitale, annonce aujourd’hui le chiffre d’affaires de son premier trimestre 2020.Elie Girard, Directeur Général, a déclaré : «...

April 22, 2020Akzo Nobel N.V. (AKZA; AKZOY) publishes results for first quarter 2020Highlights Q1 2020Adjusted operating income1 up 31% at €214 million (2019: €163 million), despite impact from COVID-19Return on Sales, excluding unallocated costs,2 increased to 12.4% (2019: 9.1%) with price/mix up 2%Operating income up 65% at €187 million (2019: €113 million); OPI margin improved to 9.1% (2019: 5.2%)Transformation and other savings delivered €44 million lower costs (compared with the first quarter of 2019)€408 million of €500 million share buyback program executed during Q1 2020Q1 2020 (compared to Q1 2019)Revenue 6% lower and 5% lower in constant currencies3, with positive price/mix of 2% more than offset by 7% lower volumes, mainly due to the impact of COVID-19Operating income at €187 million includes €27 million negative impact from...

PR No: C2954CQ1 net revenues $2.23 billion; gross margin 37.9%; operating margin 10.4%; net income $192 millionQ1 net financial position(1)$668 millionBusiness outlook at mid-point: Q2 net revenues $2.0 billion and gross margin of 34.6%Geneva, April 22, 2020 – STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, reported U.S. GAAP financial results for the first quarter ended March 28, 2020. This press release also contains non-U.S. GAAP measures (see Appendix for additional information).ST reported first quarter net revenues of $2.23 billion, gross margin of 37.9%, operating margin of 10.4%, and net income of $192 million or $0.21 diluted earnings per share.Jean-Marc Chery, STMicroelectronics President & CEO, commented:“In the first quarter of 2020,...

PR No: C2954CPremier trimestre 2020 : chiffre d’affaires net de 2,23 milliards de dollars ; marge brute de 37,9 % ; marge d’exploitation de 10,4 % ; résultat net de 192 millions de dollars ;Situation financière nette1 au premier trimestre : 668 millions de dollars ;Point médian des prévisions pour le deuxième trimestre : chiffre d’affaires net de 2,0 milliards de dollars et marge brute de 34,6 %.Genève, le 22 avril 2020 — STMicroelectronics (NYSE : STM), un leader mondial des semiconducteurs dont les clients couvrent toute la gamme des applications électroniques, annonce la publication de ses résultats financiers U.S. GAAP pour le premier trimestre clos le 28 mars 2020. Ce communiqué de presse contient également des mesures non-U.S. GAAP (voir les annexes pour des informations complémentaires).Au premier trimestre 2020, ST a enregistré...

TORONTO, April 21, 2020 (GLOBE NEWSWIRE) — SmartCentres Real Estate Investment Trust (“SmartCentres” or the “REIT”) (TSX: SRU.UN) released an update today on the impact of COVID-19 on the REIT’s business, the measures it has put in place, accordingly, and its long-term strategy.  Additional details will be provided as part of the REIT’s first quarter reporting.  Additionally, the REIT announced today that it is withdrawing any previous guidance for fiscal 2020 due to the continuing economic and operating impact resulting from the COVID-19 pandemic.SmartCentres is an open-air shopping centre REIT, 5 years into a strategy to transition into a diversified REIT through development, primarily on its owned properties, of residential, seniors housing, office, and storage facilities.  This $12.1 billion development program, underway, is...

BRISBANE, Australia, April 22, 2020 (GLOBE NEWSWIRE) — During the quarter the Olaroz Lithium Facility (Olaroz) temporarily stopped production due to Argentine government COVID-19 quarantine restrictions, which in addition to planned maintenance resulted in 21 days of lost production. Despite lower plant availability, cash cost of sales reduced by 3% quarter on quarter (QoQ). Market conditions and product pricing continued to be challenging, however operational cashflow remained positive. Work continues at the Naraha Lithium Hydroxide Plant (Naraha) while site operations at the Olaroz Stage 2 Expansion have stopped due to quarantine restrictions. In light of current operational conditions and uncertain future demand Orocobre Limited (Orocobre) has withdrawn guidance for FY20.OLAROZ LITHIUM FACILITY (ORE 66.5%)1Production for the...

TORONTO, April 21, 2020 (GLOBE NEWSWIRE) — QuestCap Inc. (“QuestCap” or the “Company”) (CSE:QSC; FRA:34C1) announced today that further to its press release of April 16, 2020, it has closed the transaction to acquired 49 per cent of the issued and outstanding shares of Athletics and Health Solutions Inc. (“A&H”). Pursuant to the agreement entered into by the Company, A&H and all of A&H’s shareholders (the “Shareholders”), QuestCap issued an aggregate of 6,000,000 of its common shares to the Shareholders in exchange for common shares of A&H totalling 49% of A&H’s issued and outstanding shares (the “Transaction”). For more information on A&H and the Transaction, please see the Company’s press release dated April 16, 2020, which is available under the Company’s profile on SEDAR at www.sedar.com and at...

BOISE, Idaho, April 21, 2020 (GLOBE NEWSWIRE) — Micron Technology, Inc. (Nasdaq: MU) announced today that it has entered into an agreement to sell $1.25 billion aggregate principal amount of its 2.497% Senior Notes due 2023 (the “notes”) pursuant to an effective shelf registration statement on file with the Securities and Exchange Commission (the “SEC”).  The offering is expected to settle on April 24, 2020, subject to customary closing conditions.Citigroup Global Markets Inc, Credit Suisse Securities (USA) LLC, and Morgan Stanley & Co. LLC are the joint book-running managers of the notes offering.The notes will bear interest at a rate of 2.497% per year. Interest on the notes will be payable semi-annually on April 24 and October 24 of each year, commencing on October 24, 2020.Micron intends to use the net proceeds of the offering...

SYDNEY, Australia, April 22, 2020 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announced that the last patient has been enrolled and safely dosed for the second cohort of the INSIGHT-004 Phase I clinical trial. This completes enrollment for the study.The trial evaluates the combination of eftilagimod alpha (“efti” or “IMP321”), an antigen presenting cell activator, with a standard dose of avelumab, a human anti-PD-L1 antibody, in patients with advanced solid malignancies. Avelumab is co-developed and co-commercialized by Merck KGaA, Darmstadt, Germany and Pfizer Inc. Initial results from the cohort of the INSIGHT-004 study are expected to be presented at a major medical conference...